Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zenith Drugs Ltd

ZENITHDRUG.NS ✓ COMPLIANTFree checks used up today ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$0.40

▲ +0.00%

Market Cap $6.94M · Vol 800

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

16.62

FWD: N/A

Market Cap

$6.94M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

17.19

Momentum

Beta

N/A

vs Market

52W High

$0.69

45.78% below

52W Low

$0.35

14.58% above

Volume

800

Avg 16.48K

P/B

0.82

Price-to-book

ROE

N/A

Return on equity

Free Float

N/A

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Zenith Drugs Ltd (ZENITHDRUG.NS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZENITHDRUG.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.29%

-7.62%

-21.96%

-16.41%

YTD

-23.90%

-38.44%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$18.32M
Net Income	$421.86K
Revenue Growth (YoY)	+41.71%
Gross Margin	24.89%
Operating Margin	3.57%
Net Profit Margin	2.30%
ROE	N/A
ROA · ROIC	3.09% · 6.22%

P/E Ratio	16.62
Forward P/E (FY1)	N/A
PEG Ratio	-0.34
P/S	0.35
P/B	0.82
P/FCF	32.89
EPS Growth	N/A
Outstanding Shares	17.15M

Technical Indicators

50-Day SMA	$0.45
200-Day SMA	$0.47
RSI (14)	17.19
Beta	N/A
52-Week High	$0.69
52-Week Low	$0.35

Volume Today	800
Avg Daily Volume (30D)	16.48K
Relative Volume	0.05x
Volatility (10D)	24.82
Volatility (30D)	71.58
Free Float	N/A

Analyst Consensus

N/A

Current Price $0.40

Mean Target N/A

52W Low$0.35 52W High$0.69

Current

Target

$0.35 $0.69

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE

FIGIBBG00LBXV9K2

ISININE0QWN01013

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +2.83% JNJ Johnson & Johnson +3.81% ABBV AbbVie Inc. +0.14% NVS Novartis AG +1.52% NOVN.S Novartis AG +1.58%

Company Profile

Zenith Drugs Ltd is an India-based pharmaceutical company. The Company is mainly engaged in the business of manufacturing and trading medicine. The Company offers generics and formulations, including ORS powder, liquid orals, ointments, liquid externals, and capsules. Its liquid oral products include Vitamin B Complex Syrup, Iron + Folic Acid + Vitamin B12 Syrup, Multivitamin Syrup, Vitamin B Complex with L Lysine Syrup, Multivitamin Drops, Paracetamol Suspension 125 mg/5 ml, Protein with Vitamin B Complex Syrup, Antacid Suspension Each 5ml, Cold Syrup (Para Cetrizine Phenylephrine), Levosalbutamol Syrup 1mg/5 ml, and others. Its ointment products include Povidone Iodine Ointment 5% W/W, Povidone Iodine + Metronidazole Ointment, Clotrimazole Cream IP 1% w/w, Fucidic Acid Cream 2%, Gentamycin Sulphate Cream 0.1%W/W, and more. Its capsule products include Omeprazole Capsule 20 mg, Tetracycline Capsule Blister 250 mg, Chloramphenicol Capsule 500 mg, and more.